Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage
pharmaceutical company focused on the development and
commercialization of therapies for patients with rare genetic
mitochondrial diseases, today announced that the company will
present four posters at the 2023 Mitochondrial Medicine Symposium.
The event, which is hosted by the United Mitochondrial Disease
Foundation (UMDF), will be held in Charlotte, N.C., from June
28 – July 1, 2023.
PosterMavodelpar Clinical
Development Program in Adult Patients with Primary Mitochondrial
Myopathy (PMM): Results from Phase 1b Study and Design of Ongoing
Pivotal Study (STRIDE)
Presenter: Will Chou, MD, Vice President, Clinical
Development and Medical AffairsDate/Time: Wednesday, June 28, 2023,
at 5:30 p.m. EDT
PosterFrom Clinical Manifestations
of Primary Mitochondrial Myopathies (PMM) to Diagnosis: Results
from a Patient Journey Analysis Shows Limited Utilization of
Genetic Testing
Presenter: Mai Sirimanne, Vice President, Clinical
AffairsDate/Time: Wednesday, June 28, 2023, at 5:30 p.m. EDT
PosterClinical Manifestations and
Disease Burden of Primary Mitochondrial Myopathies (PMM): Results
from a Patient Journey Analysis Shows Substantial Healthcare
Resource Utilization
Presenter: Mai Sirimanne, Vice President, Clinical
AffairsDate/Time: Thursday, June 29, 2023, at 5:45 p.m. EDT
PosterPPARδ Agonist Mavodelpar
(REN001) Improves Mitochondrial Function in Skeletal Muscle: A
Potential Treatment for Primary Mitochondrial Myopathies
Presenter: John Adams, Senior Vice President,
Translational ScienceDate/Time: Thursday, June 29, 2023, at 5:45
p.m. EDT
PresentationPlatform Session 5 –
Combined Sessions/Clinical Trial UpdatesReneo Primary Mitochondrial
Myopathy program update
Presenter: Alejandro Dorenbaum, MD, Chief Medical
OfficerDate/Time: Friday, June 30, 2023, at 11:30 a.m. EDT
About Reneo PharmaceuticalsReneo
is a clinical-stage pharmaceutical company focused on the
development and commercialization of therapies for patients with
rare genetic mitochondrial diseases, which are often associated
with the inability of mitochondria to produce adenosine
triphosphate (ATP). Our lead product candidate, mavodelpar
(REN001), is a potent and selective agonist of the peroxisome
proliferator-activated receptor delta (PPARδ). Mavodelpar has been
shown to increase transcription of genes involved in mitochondrial
function, increase fatty acid oxidation, and may increase
production of new mitochondria. For additional information, please
see reneopharma.com.
About MavodelparMavodelpar
(REN001) is a potent and selective peroxisome
proliferator-activated receptor delta (PPARδ) agonist currently in
clinical development for two rare genetic mitochondrial diseases
that typically present with myopathy and have high unmet medical
needs: PMM and LC-FAOD. For additional information, please
see clinicaltrials.gov.
About PMMPMM are a group of rare,
genetic metabolic disorders caused by mutations or deletions in the
mtDNA or nDNA. These genetic alterations hamper the ability of
mitochondria to generate energy from nutrient sources, resulting in
energy deficits that are most pronounced in tissues with high
energy demand such as muscle, brain, and heart. The symptoms of PMM
include muscle weakness, exercise intolerance, movement disorder,
deafness, blindness, and droopy eyelids among others. The prognosis
for these disorders ranges in severity from progressive weakness to
death.
Forward-Looking
StatementsStatements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include statements regarding, among other things, the
potential development, registration and commercialization of
mavodelpar, results, conduct, progress, plans and timing of Reneo’s
clinical trials, announcement of topline data from the STRIDE study
and dosing of our first adult patient with PMM due to nDNA defects.
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Words such as “plans,”
“will,” “believes,” “anticipates,” “expects,” “intends,” “goal,”
“potential” and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
based upon Reneo’s current expectations and involve assumptions
that may never materialize or may prove to be incorrect. Actual
results could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, risks and
uncertainties associated with Reneo’s business in general, and the
other risks described in Reneo’s filings with the Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Reneo undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
Contacts:
Danielle Spangler Investor
Relations Reneo Pharmaceuticals,
Inc. dspangler@reneopharma.com
David Melamed, Ph.D. Media
Inquiries Russo Partners,
LLC david.melamed@russopartnersllc.com
Reneo Pharmaceuticals (NASDAQ:RPHM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Reneo Pharmaceuticals (NASDAQ:RPHM)
Historical Stock Chart
From Jul 2023 to Jul 2024